Artelo Biosciences (NASDAQ:ARTL) posted its quarterly earnings data on Wednesday. The company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.02), MarketWatch Earnings reports.
Shares of ARTL traded down $0.00 during midday trading on Friday, reaching $0.43. The stock had a trading volume of 6,300 shares, compared to its average volume of 681,841. The company’s 50-day moving average is $0.66 and its 200 day moving average is $0.82. Artelo Biosciences has a 12-month low of $0.43 and a 12-month high of $3.67. The company has a market capitalization of $18.11 million, a price-to-earnings ratio of -1.19 and a beta of 2.04.
Several analysts have issued reports on the company. Zacks Investment Research upgraded Artelo Biosciences from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Thursday, December 2nd. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Artelo Biosciences in a research note on Tuesday, November 30th. Finally, Maxim Group began coverage on Artelo Biosciences in a research note on Friday, October 8th. They issued a “buy” rating and a $3.00 target price on the stock.
About Artelo Biosciences
Artelo Biosciences, Inc is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal.
Recommended Story: How to interpret Moving Average Convergence Divergence (MACD)
Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.